Article Text

other Versions

PDF
Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women
  1. Philippe Mayaud (philippe.mayaud{at}lshtm.ac.uk)
  1. London School of Hygiene and Tropical Medicine, United Kingdom
    1. Nicolas Nagot (n_nagot{at}hotmail.com)
    1. University of Montpellier 1, France
      1. Issouf Konate (kletio{at}yahoo.fr)
      1. Centre Muraz, Bobo-Dioulasso, Burkina Faso
        1. Abdoulaye Ouedraogo (ouarma74{at}yahoo.fr)
        1. Centre Muraz, Bobo-Dioulasso, Burkina Faso
          1. Helen A Weiss (helen.weiss{at}lshtm.ac.uk)
          1. London School of Tropical Medicine and Hygien, United Kingdom
            1. Vincent Foulongne (v-foulongne{at}chu-montpellier.fr)
            1. University of Montpellier-1, France
              1. Marie-Christine Defer (mcdefer{at}yahoo.fr)
              1. Centre Muraz, Bobo-Dioulasso, Burkina Faso
                1. Adrien B Sawadogo (sawadogoadrien{at}yahoo.fr)
                1. CHU Bobo-Dioulasso, Burkina Faso
                  1. Michel Segondy (m-segondy{at}chu-montpellier.fr)
                  1. University of Montpellier-1, France
                    1. Philippe van de Perre (p-van_de_perre{at}chu-montpellier.fr)
                    1. University of Montpellier-1, France

                      Abstract

                      Objectives: To document the natural history of herpes simplex virus type-2 (HSV-2) in relation to HIV and HAART in Africa, we conducted a longitudinal study of women in the placebo arms of two randomised controlled trials of HSV suppressive therapy in Burkina Faso.

                      Methods: 22 HIV-uninfected women (Group 1), 30 HIV-1-infected women taking HAART (Group 2), and 68 HIV-1-infected women not eligible for HAART (Group 3) were followed over 24 weeks. HSV-2 DNA was detected on alternate weeks using real-time PCR from cervico-vaginal lavages. Plasma HIV-1 RNA was measured every month. CD4 counts were measured at enrolment.

                      Results: Ulcers occurred on 1.9%, 3.1% and 7.2% of visits in groups 1, 2 and 3 (p=0.02). Cervico-vaginal HSV-2 DNA was detected in 45.5%, 63.3% and 67.6% of women (p=0.11), and on 4.3%, 9.7% and 15.5% of visits in the three groups (p<0.001). Among HIV-infected women, cervico-vaginal HSV-2 DNA was detected more frequently during ulcer episodes (adjusted risk ratio [aRR] 2.79, 95% confidence interval [CI] 2.01-3.86) and less frequently among women practising vaginal douching (aRR 0.60, 95%CI 0.40-0.91). Compared with women not taking HAART and with CD4 count >500 cells/µL, women on HAART had a similar risk of HSV-2 shedding (aRR 0.95, 95%CI 0.52-1.73), whilst women with CD4 count 200-500 cells/µL were more likely to shed HSV-2 (aRR 1.71, 95%CI 1.02-2.86).

                      Conclusions: HSV-2 reactivations occur more frequently among HIV-infected women, particularly those with low CD4 counts, and are only partially reduced by HAART. HSV therapy may benefit HIV-infected individuals during HAART.

                      Statistics from Altmetric.com

                      Request permissions

                      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

                      Linked Articles

                      • Brief encounters
                        Helen Ward Rob Miller